MINNEAPOLIS & ORLANDO, Fla.--(BUSINESS WIRE)--Results from the IRIS (Immediate Risk Stratification Improves Survival) clinical trial, supported in part by Medtronic, Inc. (NYSE: MDT) and presented today at the 58th Annual Scientific Session of the American College of Cardiology, showed that sudden cardiac death in a specific subset of immediate post-MI (myocardial infarction) patients was statistically significantly reduced with implantable cardioverter-defibrillator (ICD) therapy. However, in this narrowly defined patient population, ICDs did not reduce mortality from all causes, as all causes are not treatable by ICDs.
